You will be able to use the M1 for many different applications, especially on the head and neck area.
Hi Martin, just wanted to see how things are progressing since your last post. hope all is well with you and your mom!
What’s fascinating are the studies on PD and the enteric nervous system. In our own case (not aging elderly but child) we have seen gut issues and enteric nervous system damage caused by autoimmunity to a protein that lines the ENS nerves, cause memory and cognitive decline. Working on reversing that. ICES PEMF on the gut is the only thing that has shown to improve the cognition in this case. However, there is signficant flare/die off in our case so we having to go up super slowly. Currently at 15 minutes daily.
2 Likes
wow… do you know the origin/cause of all this?
Fascinating! Thanks for pointing that out. Do you know about the connection with dopamine and the standard theories about PD?
Yes, I have read several of those studies. Unfortunately, it is all too real - we have seen our aging neighbor with PD decline heavily the last couple years.
I’ve knew once a woman which husband had PD. The stuff they “clinically” use I find very crude: NDMA-antagonists, MAO-B antagonists, COMT-antagonists, L-Dopa + Dopa-carboxylase antagonists. They all increase dopamine to a toxic level, so they kill the PD people that way.
They completely miss the big picture of micronutrient deficiencies, some core genetic defects like HPU, common detox problems, MTHF, PEMT and especially mercury and other dental issues like root canals and CAP. Also they do mostly no genetic tests for COMT and MAO-A/B polymorphisms.
Stone-age treatment…
Best,
Hans
1 Like
This was my exploration of Parkinson’s with AI… interesting info about the disease… and THIS is why ICES PEMF helped for advanced Parkinson’s.
Dopamine and Parkinson’s Disease
Dopamine is a neurotransmitter, a chemical messenger that helps brain cells communicate. It plays a crucial role in movement, mood, and reward systems.
In Parkinson’s disease, there’s a progressive loss of dopamine-producing nerve cells in a specific area of the brain called the substantia nigra. This loss of dopamine disrupts communication between brain cells, leading to the characteristic motor symptoms like tremors, stiffness, and slowness of movement.
While the exact mechanism of how dopamine loss causes these symptoms is still being researched, it’s believed to involve imbalances in brain circuits responsible for movement control.
The substantia nigra is located in the midbrain. It’s a small, dark-colored structure that plays a crucial role in controlling movement.
Inflammation and Parkinson’s Disease
Inflammation is indeed a significant factor in Parkinson’s disease. While it’s not the sole cause, it’s believed to play a crucial role in both the development and progression of the disease.
Chronic inflammation can damage dopamine-producing neurons, contributing to their loss. It can also exacerbate the symptoms of Parkinson’s by creating a hostile environment for brain cells.
Researchers are actively investigating the role of inflammation in Parkinson’s and exploring potential anti-inflammatory treatments.
Removing Inflammation: A Hypothetical Scenario
If we could hypothetically and completely remove inflammation from the equation in Parkinson’s disease, we would likely see several positive effects:
- Slower disease progression: Without the constant assault of inflammation, dopamine-producing neurons might be better protected, leading to a slower decline in motor function.
- Reduced symptoms: Inflammation can exacerbate existing symptoms like stiffness and pain. Eliminating it could potentially improve a person’s quality of life.
- Better response to treatment: Current therapies might become more effective in a less inflamed environment.
Let’s delve into the fascinating realm of targeting inflammation as a potential therapeutic avenue for Parkinson’s disease.
Current research suggests that reducing inflammation might offer several benefits for individuals with Parkinson’s:
Neuroprotection:
- By mitigating the damaging effects of inflammation on brain cells, we might be able to slow down the loss of dopamine-producing neurons and delay disease progression.
Symptom Management:
- Targeting inflammation could potentially alleviate some of the motor and non-motor symptoms associated with Parkinson’s disease.
- This might lead to improved quality of life and greater independence for individuals living with the condition.
Enhancing Treatment Efficacy:
- Reducing inflammation might create a more favorable environment for existing therapies to work more effectively.
- This could potentially improve motor function and potentially delay the need for more invasive treatments.
Several strategies are being explored to target inflammation in Parkinson’s disease:
Anti-inflammatory drugs:
- Repurposing existing anti-inflammatory drugs or developing new ones specifically for Parkinson’s.
Lifestyle interventions:
- Promoting a healthy diet and exercise regimen to reduce systemic inflammation.
Immunomodulatory therapies:
- Targeting specific immune pathways involved in inflammation.
While research in this area is still ongoing, the potential benefits of targeting inflammation in Parkinson’s are promising.
If successful, these approaches could significantly improve the lives of individuals with this challenging disease.
This makes a lot of sense to me, thanks.